Ground substance

Silver Spike Investment Corp. Reports First Quarter 2024 Financial Results and Announces Cash Dividend of $0.25 Per Share

Retrieved on: 
Giovedì, Maggio 9, 2024

The dividend is payable on June 28, 2024 to stockholders of record on June 20, 2024.

Key Points: 
  • The dividend is payable on June 28, 2024 to stockholders of record on June 20, 2024.
  • Based on this news and an expected acceleration in refinancings, we anticipate an increase in cannabis capital markets activity in the second half of 2024.
  • As of March 31, 2024, the Company had $33.2 million in available liquidity, comprising $33.2 million in cash equivalents.
  • The Company will host a conference call and webcast to discuss the Company's first quarter 2024 financial results at 8:00 a.m. Eastern Time on Friday, May 10, 2024.

Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research

Retrieved on: 
Giovedì, Maggio 9, 2024

Optimi has obtained the Export Permit required from Health Canada for the shipment of its in-house manufactured MDMA active pharmaceutical ingredient (API) to IPR-TLV.

Key Points: 
  • Optimi has obtained the Export Permit required from Health Canada for the shipment of its in-house manufactured MDMA active pharmaceutical ingredient (API) to IPR-TLV.
  • With the Export Permit confirmed, Optimi will be one of the first psychedelics pharmaceutical manufacturers to ship MDMA to the country.
  • "Partnering with IPR-TLV and shipping MDMA to Israel marks a significant advancement for Optimi," said Bill Ciprick, CEO of Optimi Health.
  • Optimi Health Chief Financial Officer, Jacob Safarik, commented, "Obtaining an Export Permit to ship controlled substances globally involves a meticulous process that demands collaboration from various stakeholders.

Statement from the Minister of Mental Health and Addictions and Associate Minister of Health

Retrieved on: 
Martedì, Maggio 7, 2024

BC has asked that we make amendments to its project and we are granting BC's request to prohibit possession of controlled substances in public spaces.

Key Points: 
  • BC has asked that we make amendments to its project and we are granting BC's request to prohibit possession of controlled substances in public spaces.
  • Everyone deserves to feel safe in their communities.
  • Law enforcement also needs to have additional tools to address issues of public safety while continuing to take a compassionate and public health approach to addressing substance use harms.
  • Working together, we can continue to adapt and adjust our approach to reflect the evidence and what is actually working on the ground.

Nanalysis Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Lunedì, Aprile 29, 2024

Gross margin percentage on product sales was 41% for the twelve months ended December 31, 2023, down from 49% in the prior year.

Key Points: 
  • Gross margin percentage on product sales was 41% for the twelve months ended December 31, 2023, down from 49% in the prior year.
  • Because of these cost-cutting measures, as well as improved sales markets, gross margin percentage on product sales rose to 48% in the fourth quarter.
  • Services gross margin percentage was (23%) for the twelve months ended December 31, 2023.
  • EBITDA loss for the twelve months ended December 31, 2023, was $8,074K versus an EBITDA loss of $3,935K in the same period last year.

Constellation Brands Announces Conversion of Common Shares and Exchange of Promissory Note Into Exchangeable Shares of Canopy Growth Corporation

Retrieved on: 
Giovedì, Aprile 18, 2024

VICTOR, N.Y., April 18, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that its indirect, wholly-owned subsidiaries, Greenstar Canada Investment Limited Partnership (“Greenstar”) and CBG Holdings LLC (“CBG”), have converted (the "Conversion”) their common shares (“Common Shares”) of Canopy Growth Corporation (“Canopy”) into non-voting and non-participating exchangeable shares of Canopy (“Exchangeable Shares”).

Key Points: 
  • VICTOR, N.Y., April 18, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that its indirect, wholly-owned subsidiaries, Greenstar Canada Investment Limited Partnership (“Greenstar”) and CBG Holdings LLC (“CBG”), have converted (the "Conversion”) their common shares (“Common Shares”) of Canopy Growth Corporation (“Canopy”) into non-voting and non-participating exchangeable shares of Canopy (“Exchangeable Shares”).
  • Greenstar and Canopy also agreed to exchange (the “Note Exchange” and together with the Conversion, the “Transactions”) C$81.2 million of the principal amount of the C$100 million promissory note due December 2024 issued by Canopy (the “Note”) for Exchangeable Shares pursuant to an exchange agreement between Greenstar and Canopy (the “Exchange Agreement”).
  • For early warning reporting purposes, Constellation will be deemed to beneficially own the Common Shares issuable on conversion of the Exchangeable Shares.
  • Based on the assumptions noted above and assuming no further issuances of Common Shares or Exchangeable Shares, if Constellation were to convert all such Exchangeable Shares into Common Shares it would hold an aggregate of 26,261,474 Common Shares (representing approximately 26.2% of the currently issued and outstanding Common Shares, inclusive of the as-converted Exchangeable Shares).

Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)

Retrieved on: 
Lunedì, Aprile 15, 2024

VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s Precursor Licence.

Key Points: 
  • VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s Precursor Licence.
  • As previously communicated in January , Optimi employed the precursor 3,4-Methylenedioxyphenyl-2-propanone (MDP2P) to guarantee the quality and uniformity of the MDMA API manufacturing process.
  • The production of this MDMA API was produced in-house, explicitly for the recently disclosed supply agreement with the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV) in Israel.
  • Bill Ciprick, CEO of Optimi, confirms that the MDMA was tested and validated by a third-party laboratory, therefore meeting the Company’s quality assurance standards.

Indie Games Burst Onto Nintendo Switch Promising Adventure, Cozy Vibes, and Curious Cat Mischief

Retrieved on: 
Mercoledì, Aprile 17, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240417156103/en/
    Little Kitty, Big City releases on Nintendo Switch on May 9.
  • The Purribean is yours to explore when Cat Quest III launches for Nintendo Switch on Aug. 8.
  • For the latest news and updates about indie games on Nintendo Switch, follow the Indie World X account @IndieWorldNA and check out https://www.nintendo.com/us/indie-world/news/ .
  • * Any Nintendo Switch Online membership (sold separately) and Nintendo Account required for online features.

PolyU researchers introduce biomineralisation as sustainable strategy against microbial corrosion in marine concrete

Retrieved on: 
Mercoledì, Aprile 10, 2024

In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.

Key Points: 
  • In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.
  • This biomineralisation strategy has strong potential for applications in corrosive environments, such as in marine and sewage settings, and water-cooling utilities, where concrete corrosion is induced by corrosive microorganisms.
  • A paper reporting the research, " Biomineralisation to prevent microbially induced corrosion on concrete for sustainable marine infrastructure ", has been published in Environmental Science & Technology.
  • The results contribute to the development of new techniques for inhibiting corrosion to achieve sustainable marine concrete structures.

PolyU researchers introduce biomineralisation as sustainable strategy against microbial corrosion in marine concrete

Retrieved on: 
Mercoledì, Aprile 10, 2024

In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.

Key Points: 
  • In response to the need for an effective solution to combat marine corrosion in concrete, The Hong Kong Polytechnic University (PolyU) researchers have developed a biomineralisation approach to protect marine concrete from MIC.
  • This biomineralisation strategy has strong potential for applications in corrosive environments, such as in marine and sewage settings, and water-cooling utilities, where concrete corrosion is induced by corrosive microorganisms.
  • A paper reporting the research, " Biomineralisation to prevent microbially induced corrosion on concrete for sustainable marine infrastructure ", has been published in Environmental Science & Technology.
  • The results contribute to the development of new techniques for inhibiting corrosion to achieve sustainable marine concrete structures.

Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute

Retrieved on: 
Martedì, Aprile 9, 2024

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is proud to announce the signing of an international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute (Mātai), on behalf of the Tū Wairua Project.

Key Points: 
  • VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is proud to announce the signing of an international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute (Mātai), on behalf of the Tū Wairua Project.
  • This agreement marks Optimi's first supply deal to New Zealand, a significant milestone for the company's global expansion efforts.
  • Under the terms of the agreement, Optimi will provide Mātai with a quantity of its validated GMP Full Spectrum Natural Psilocybin extract.
  • Further, the agreement includes tracked stability of the extract, ensuring the highest standards of GMP quality and compliance.